Skip to main content
. 2020 Nov 10;8(2):e001240. doi: 10.1136/jitc-2020-001240

Figure 3.

Figure 3

Characteristics of objective response in patients with camrelizumab plus gemcitabine and oxaliplatin (GEMOX). (A) Duration of response (N=20). (B) The maximum percentage reduction from baseline in target lesions (N=36). One patient discontinued because of treatment-related adverse effect before first radiographic assessment and was not included.